Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical firm Bristol Myers Squibb invested an undisclosed amount in US-based programmable cell therapy developer ArsenalBio yesterday through a collaboration deal focusing on T cell therapies to treat solid tumours. The partnership deal includes a $70m upfront payment and it comes after ArsenalBio launched in October 2019 with $85m in series A funding from investors…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.